Relevant Research Publications
*Important note here - this is absolutely NOT every single published piece of data on Menopause. Consider this a Rise-style roundup of what we consider to be important, published research available to date.
Women’s Health Initiative (WHI)
The study that launched a thousand headlines—and a nationwide panic. The WHI was a massive, federally funded trial examining hormone therapy, diet, and calcium/vitamin D in postmenopausal women. It studied post-menopausal women aged 50-79. It reshaped how clinicians talk about MHT risks and benefits.
Key findings: Combined estrogen‑progestin therapy increased risks of CHD, stroke, VTE, and breast cancer; (oral) estrogen‑only increased stroke/VTE. Long‑term follow‑up found no difference in all‑cause mortality over 18 years. MHT used in this study was CEE (oral conjugated equine estrogen) and MPA (medroxyprogesterone acetate), both of which have fallen out of favor to bioidentical options such as estradiol and progesterone.
Why it matters: It reframed hormone therapy as favorable in osteoporosis prevention and symptom treatment, but not as a primary prevention heart‑disease strategy. Started the conversation about risks vs benefits of MHT, and lead to all the post hoc data we have now!
Link: https://www.nhlbi.nih.gov/science/womens-health-initiative-whi(nhlbi.nih.gov in Bing)
WHI - Post-Hoc Analysis
The “okay, let’s calm down and look again” follow‑up. Long‑term mortality and health outcomes after the original WHI hormone therapy trials. After the initial WHI results caused nationwide panic, researchers spent years re‑examining the data with more nuance. These post‑hoc analyses helped clarify who was actually at risk, why, and how timing matters. They’re the reason modern menopause care looks very different from the early‑2000s fear‑based approach.
Here are the key takeaways:
1. Age / time since Menopause Matters - A Lot
Women who started hormone therapy before age 60 or within 10 years of menopause had:
Lower all‑cause mortality
Lower coronary heart disease risk
Better overall outcomes compared to older starters
This became the foundation of the “window of opportunity” concept
Key findings: No difference in all‑cause mortality between HT and placebo groups over 18 years.
Why it matters: Helps contextualize early WHI findings and reduce lingering fear.
Link: https://jamanetwork.com/journals/jama/fullarticle/2653735(jamanetwork.com in Bing)
2. Estrogen - only therapy looks very different than combined MHT
In women with hysterectomy, estrogen‑only therapy:
Did not increase breast cancer risk
Was associated with lower breast cancer incidence and mortality in long‑term follow‑up
Showed no increase in heart disease risk in younger women
3. The risks in Older women were about timing, not necessarily the Estrogen itself
Women who started HT after age 60 or more than 10 years past menopause had higher risks of:
Stroke
VTE
Coronary events
4. No Difference in All-Cause Mortality Over 18 years
The WHI 18‑year follow‑up showed no difference in overall mortality between HT users and placebo. This helped calm lingering fears and reframed HT as a safe, evidence‑based option for the right candidates.
5. Quality of Life Improvements Were Real
Post‑hoc analyses confirmed significant improvements in:
Vasomotor symptoms
Sleep
Sexual function
Mood
Overall well‑being
These benefits were under‑reported in early WHI publications.
6. Duration-dependent breast cancer risk with combined therapy remains real
Risk may increase with longer combined estrogen and progestogen use, though is without significant effect within 5-7 years. While estrogen alone carries lower risk.
7. Progestogen used and the route still matter
Lower doses of Transdermal estradiol with micronized progesterone appears safer for thrombotic and stroke risk in observational data. And micronized progesterone may be more favorable than synthetic progestins for breast cancer. Neither of this has been demonstrated in RCT’s.
Links:
WHI Age-Stratified Outcomes (Rossouw et al.) https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/1108760(jamanetwork.com in Bing)
WHI 18-Year Mortality Follow up (Manson et al.) https://jamanetwork.com/journals/jama/fullarticle/2653735(jamanetwork.com in Bing)
Breast Cancer Outcomes -Estrogen Only Arm (Chlebowski et al.) https://pubmed.ncbi.nlm.nih.gov/25693050/(pubmed.ncbi.nlm.nih.gov in Bing)
Cardiovascular Timing Hypothesis (Manson et al.) https://pubmed.ncbi.nlm.nih.gov/24084921/(pubmed.ncbi.nlm.nih.gov in Bing)
Menopausal Hormone Treatment and Breast Cancer (Gompel et al.)
Menopausal hormone treatment and breast cancer - PubMed
Menopausal Hormone Therapy and Breast Cancer: Balancing Risks and Benefits (Bollam et al.)
www.sciencedirect.com/science/article/abs/pii/S037851222600071X
The Women’s Health Initiative Randomized Trials and Clinical Practice (Manson et al.)
Long-Term Hormone Therapy for Perimenopausal and Postmenopausal Women (Rodriguez et al.)
Long-term hormone therapy for perimenopausal and postmenopausal women - PubMed
Study of Women’s Health Across the Nation (SWAN)
The “what is happening to me?” study—but with data. This showed us what menopause does to our bodies. A long‑running, diverse cohort study tracking women through the menopausal transition. Women aged 42-52, followed annually for > 2 decades.
Key findings: Hot flashes aren’t just annoying—they correlate with cardiometabolic risk and vascular changes. This study helped map symptom patterns across race, ethnicity, and socioeconomic factors. Showed menopause as a period of accelerated change in bone, body composition, lipids and vascular health. Earlier the symptom onset predicts a longer course, with African American women having the longest duration.
Why it matters: It helps clinicians understand who experiences what symptoms, when, and why. It’s not in your head!
Kronos Early Estrogen Prevention Study (KEEPS Trial)
The “modern hormone therapy” trial. KEEPS evaluated low‑dose, more contemporary hormone therapy regimens in recently menopausal women. Included low risk / healthy women aged 42-58. Compared oral CEE versus transdermal estradiol, each with cycled oral micronized progesterone.
Key findings: No progression in CIMT (carotid intima-media thickness) over 4 years, and no increase in severe cardiovascular or cognitive events in either regimen. Both regimens improved sleep, vasomotor symptoms and sexual function. CEE improved mood states. Transdermal estradiol was lipid neutral. Original trial was 4 years.
Why it matters: It showed that WHI‑era regimens aren’t the only story—modern HT looks very different. Shows safety data in the population underrepresented in the WHI.
Link: https://pubmed.ncbi.nlm.nih.gov/24094567/(pubmed.ncbi.nlm.nih.gov in Bing)
MsHeart / MsBrain Studies
The “your hot flashes are trying to tell you something” studies. These sub‑studies examine how vasomotor symptoms relate to cardiovascular and brain health. Observational, complementary counterpart to the SWAN.
Key findings: Frequent hot flashes correlate with worse cardiometabolic markers and white‑matter brain changes.
Why it matters: Hot flashes can be a health signal—not just a nuisance. Consistent with AHA’s position of the menopause transition as a prevention window for risk factor optimization.
Link: https://pubmed.ncbi.nlm.nih.gov/?term=MsHeart+MsBrain(pubmed.ncbi.nlm.nih.gov in Bing)
MsFLASH Trials
The “does this actually help?” research network. A series of randomized trials comparing non‑hormonal treatments for vasomotor symptoms.
Key findings: SSRIs/SNRIs (like venlafaxine or escitalopram) reduce hot flashes about as much as low‑dose estradiol. CBT‑I improves sleep.
Why it matters: It gives women real alternatives when hormones aren’t an option.
Link: https://clinicaltrials.gov/search?term=MsFLASH (clinicaltrials.gov in Bing)
Early vs. Late Intervention Trial with Estradiol (ELITE Trial)
Timing matters. ELITE tested whether starting estradiol early vs. late after menopause affected cardiovascular outcomes. Oral estradiol with vaginal micronized progesterone used in the trial; enrolled healthy postmenopausal women.
Key findings: Women who started HT within 6 years of menopause had slower progression of carotid artery thickening.
Why it matters: Supports the “window of opportunity” concept for HT, and that dose should be chosen for symptoms control / tolerability over potential vascular benefit.
Link: https://pubmed.ncbi.nlm.nih.gov/26901505/ (pubmed.ncbi.nlm.nih.gov in Bing)
DOPS Trial (Danish Osteoporosis Prevention Study)
The DOPS trial is a reassuring piece of menopause research. They looked at women who were recently menopausal (aged 45-58) —you know, the actual group who typically seeks hormone therapy. HOWEVER, this study has been rightly criticized for lack of blinding and being relatively small.
Key findings: Women who started HT early in menopause had lower risks of heart disease and death compared to women who didn’t use HT. No increase in breast cancer, stroke or blood clots during the 10-year treatment period. Some benefits continued even after stopping therapy.
Why it matters: Supports the window of opportunity / timing hypothesis, with reassuring on cardiovascular (CV) safety. Again, does not support HT use for primary prevention of CV events or chronic conditions.
Link: https://pubmed.ncbi.nlm.nih.gov/23169869/(pubmed.ncbi.nlm.nih.gov in Bing)
SKYLIGHT Trials (Fexolinetant = Veozah)
The “finally, a non‑hormonal option that actually works” trials. Phase 3 trials evaluating fezolinetant, the first NK3 receptor antagonist approved for hot flashes. Studied women aged 40-65 with moderate-severe hot flashes.
Key findings: 60–70% reduction in hot flashes at 52 weeks; stable safety profile. Black box warning for liver injury.
Why it matters: A strong non‑hormonal option for vasomotor symptoms.
Link: https://pubmed.ncbi.nlm.nih.gov/?term=fezolinetant+SKYLIGHT (pubmed.ncbi.nlm.nih.gov in Bing)
Oasis Trial (Elinzanetant = Lynkuet)
Another promising non‑hormonal therapy entering the chat. Dual NK1/NK3 receptor antagonist tested for vasomotor symptoms (VMS). Studied post-menopausal women aged 40-65 with moderate to severe VMS.
Key findings: ~65% reduction in hot flashes at 12 weeks; improvements in sleep and quality of life.
Why it matters: Expands the non‑hormonal treatment landscape.
Link: https://pubmed.ncbi.nlm.nih.gov/?term=OASIS+elinzanetant (pubmed.ncbi.nlm.nih.gov in Bing)
